Mutagenesis after therapy for Hodgkin's disease

K. T. Kelsey, M. Caggana-Aviles, P. Mauch, C. N. Coleman, L. N. Shulman, H. L. Liber

Research output: Contribution to journalReview articlepeer-review

Abstract

Therapy for Hodgkin's disease has been associated with a significant increase in risk for second cancers. To begin an investigation of the association of therapy-induced genetic damage with this risk, somatic mutations at the hypoxanthine phosphoribosyltransferase locus were measured in lymphocytes from patients previously treated for Hodgkin's disease. The results demonstrate that a subset of patients have persistently elevated mutation frequencies, perhaps suggesting that these individuals are among those at significant risk of second cancer development.

Original languageEnglish (US)
Pages (from-to)353-367
Number of pages15
JournalHematology/Oncology Clinics of North America
Volume7
Issue number2
DOIs
StatePublished - 1993

ASJC Scopus subject areas

  • Hematology
  • Oncology

Fingerprint Dive into the research topics of 'Mutagenesis after therapy for Hodgkin's disease'. Together they form a unique fingerprint.

Cite this